SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations
Sign Up to like & getrecommendations! Published in 2020 at "iScience"
DOI: 10.1016/j.isci.2020.101832
Abstract: Summary Tepotinib is an oral MET inhibitor approved for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations. Examining treatment-naive or tepotinib-resistant cells with MET amplification or METex14 skipping mutations identifies… read more here.
Keywords: response tepotinib; influences therapeutic; shp2 inhibition; inhibition influences ... See more keywords